Showing posts with label MET. Show all posts
Showing posts with label MET. Show all posts

April 30, 2022

Dividend Increases Week 17 (Part 1)



 

In this article, I will go through the weekly dividend increases and cuts in popular and well-known stocks. (Member of The Dividend Champions or Canadian All-Star list)

 

Recently, 25 companies announced dividend increases. Note that no dividend cuts or suspensions were announced during this period. This is the first part of the week’s notifications.

 

The table below summarises the dividend change announcements.  The table shows the current dividend, the new dividend and the percentage increase (%). Dividends are shown on an annual basis and in US dollars unless otherwise stated. Yield is the new dividend yield of the most recent price, and Years is the years of consecutive dividend increases.

January 7, 2022

Notable Analyst Upgrades and Downgrades for Week of January 3 2022 (Part 2)



 

Upgrades:

 


Kimco Realty (NYSE:KIM) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating in a research report issued on Wednesday, Analyst Ratings Network reports. The brokerage currently has a $27.00 target price on the real estate investment trust's stock. Argus' price objective indicates a potential upside of 7.02% from the stock's previous close.

KIM has been the topic of a number of other research reports. Evercore ISI upgraded Kimco Realty from an "in-line" rating to an "outperform" rating and lifted their target price for the company from $24.00 to $26.00 in a research report on Monday, November 22nd. Wolfe Research initiated coverage on Kimco Realty in a research report on Thursday, September 23rd. They issued a "market perform" rating and a $24.00 target price on the stock. Citigroup lifted their target price on Kimco Realty from $26.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, December 2nd. Truist lifted their target price on Kimco Realty from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Friday, December 10th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kimco Realty from a "buy" rating to a "hold" rating and boosted their price objective for the company from $24.00 to $26.00 in a report on Monday. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $25.60. Read more …

 


MetLife (NYSE:MET) was upgraded by Evercore ISI from an "in-line" rating to an "outperform" rating in a report issued on Wednesday, Price Targets.com reports. The brokerage presently has a $75.00 price objective on the financial services provider's stock, up from their previous price objective of $67.00. Evercore ISI's price objective suggests a potential upside of 15.49% from the company's current price.

Several other research analysts also recently weighed in on MET. The Goldman Sachs Group assumed coverage on shares of MetLife in a research report on Thursday, December 2nd. They issued a "buy" rating and a $77.00 target price on the stock. Wells Fargo & Company dropped their target price on shares of MetLife from $75.00 to $74.00 and set an "overweight" rating on the stock in a research report on Tuesday. Barclays boosted their price objective on shares of MetLife from $69.00 to $72.00 and gave the company an "overweight" rating in a research report on Tuesday, October 12th. Finally, Morgan Stanley boosted their price objective on shares of MetLife from $74.00 to $75.00 and gave the company an "overweight" rating in a research report on Thursday, October 14th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MetLife has an average rating of "Buy" and an average price target of $69.29. Read more …

 


Pfizer (NYSE:PFE) was upgraded by Bank of America from a "neutral" rating to a "buy" rating in a report released on Wednesday, The Fly reports.

Several other research firms have also weighed in on PFE. Sanford C. Bernstein raised their price objective on shares of Pfizer from $44.00 to $65.00 and gave the company a "market perform" rating in a research report on Monday. UBS Group upgraded shares of Pfizer from a "neutral" rating to a "buy" rating and raised their target price for the stock from $52.00 to $60.00 in a report on Monday, December 13th. Truist raised their target price on shares of Pfizer from $43.00 to $58.00 and gave the stock a "buy" rating in a report on Wednesday, November 24th. JPMorgan Chase & Co. set a $53.00 target price on shares of Pfizer in a report on Monday, December 13th. Finally, Barclays set a $54.00 target price on shares of Pfizer in a report on Tuesday. Nine analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $56.15. Read more …

 

 


Suncor Energy (NYSE:SU) (TSE:SU) was upgraded by equities research analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating in a report released on Wednesday, The Fly reports.

A number of other analysts have also recently commented on SU. Credit Suisse Group upped their price objective on shares of Suncor Energy from C$36.00 to C$42.00 and gave the company an "outperform" rating in a research report on Tuesday, November 2nd. BMO Capital Markets upped their price objective on shares of Suncor Energy from C$39.00 to C$43.00 and gave the company an "outperform" rating in a research report on Friday, October 29th. TD Securities increased their target price on Suncor Energy from C$39.00 to C$40.00 and gave the stock a "buy" rating in a report on Thursday, October 28th. Scotiabank increased their target price on Suncor Energy from C$33.00 to C$37.00 and gave the stock an "outperform" rating in a report on Friday, November 19th. Finally, JPMorgan Chase & Co. upgraded Suncor Energy from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $29.00 to $39.00 in a report on Thursday, October 28th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $37.86. Read more …